Aspen Pharmacr (OTCMKTS:APNHY) – Jefferies Group decreased their FY2020 earnings per share (EPS) estimates for Aspen Pharmacr in a report released on Thursday. Jefferies Group analyst J. Vane-Tempest now anticipates that the company will earn $1.70 per share for the year, down from their previous forecast of $1.90. Jefferies Group also issued estimates for Aspen Pharmacr’s FY2021 earnings at $1.85 EPS and FY2022 earnings at $2.00 EPS.
Separately, Zacks Investment Research upgraded Aspen Pharmacr from a “hold” rating to a “buy” rating and set a $25.00 price target on the stock in a research note on Thursday, October 26th.
ILLEGAL ACTIVITY NOTICE: “Brokers Offer Predictions for Aspen Pharmacr’s FY2020 Earnings (APNHY)” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.americanbankingnews.com/2017/12/02/brokers-offer-predictions-for-aspen-pharmacrs-fy2020-earnings-apnhy.html.
Receive News & Ratings for Aspen Pharmacr Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aspen Pharmacr and related companies with MarketBeat.com's FREE daily email newsletter.